Open AccessFurther study of circulating IgG antibodies to CD 25‐derived peptide antigens in nonsmall cell lung cancer
Author(s) -
Chen Cairen,
Wang Weili,
Meng Qingyong,
Wu Ning,
Wei Jun
Publication year - 2016
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.12034
Subject(s) - antigen , antibody , lung cancer , immunology , medicine , cancer , immunoglobulin g
A recent study reported that circulating antibodies to CD 25‐derived peptide antigens were significantly higher in patients with nonsmall cell lung cancer ( NSCLC ) than control subjects. The present study was, thus, undertaken to replicate the initial finding with different sample sets. An in‐house ELISA was applied to determine circulating IgG antibodies to linear peptide antigens derived from CD 25. A total of 111 patients with NSCLC and 216 control subjects were recruited and divided into the discovery sample (51 vs 108) and the validation sample (60 vs 108) based on the time of sampling. Student's t test showed that circulating anti‐ CD 25 IgG levels were significantly higher in the patient group than the control group ( t = 2.23, P = 0.027) and the validation sample replicated this finding ( t = 3.31, P = 0.0012), generating a combined P value of 0.0004 (χ 2 = 20.8, df = 4). Fisher's combining probability revealed that patients with stage IV NSCLC had a significant increase in anti‐ CD 25 IgG levels compared with control subjects (χ 2 = 22.1, df = 4, P = 0.0002) but those with the other three stages did not. This study suggests that circulating anti‐ CD 25 IgG antibodies may have prognostic rather than early diagnostic values for lung cancer.